Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2012 Results
Date:5/8/2012

WASHINGTON, May 8, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the first quarter ended March 31, 2012.

Key Highlights:

  • The tasimelteon Non-24-Hour Disorder (Non-24) program continues to advance towards the goal of a projected mid-2013 New Drug Application (NDA) filing with the U.S. Food and Drug Administration (FDA).  Vanda expects to complete the two Phase III efficacy studies, SET and RESET, by the end of 2012.
  • Initial clinical data in the RESET study revealed potential of tasimelteon to reset the body clock in Non-24. 
  • The tasimelteon MAGELLAN Phase IIb/III efficacy study for Major Depressive Disorder (MDD) is ongoing and Vanda expects to report top-line results in the first half of 2013.
  • On April 16, 2012, Vanda announced that it had obtained exclusive world-wide rights from Eli Lilly and Company to develop and commercialize VLY-686, a small molecule neurokinin 1 receptor (NK-1R) antagonist for all human indications.  VLY-686 is a Phase II ready program.
  • Vanda recorded first quarter 2012 revenue of $8.1 million including royalties of $1.5 million.  Fanapt® prescriptions, as reported by IMS, reached 35,000 for the first quarter of 2012.  This represents a 39% increase over first quarter 2011 prescriptions.
  • FIRST QUARTER 2012 REPORTED RESULTSTotal revenues for the first quarter of 2012 were $8.1 million, compared to $7.5 million for the same period in 2011.  First quarter 2012 revenues included $1.5 million in Fanapt® royalties received from Novartis as compared to royalties of $0.9 mill
    '/>"/>

    SOURCE Vanda Pharmaceuticals Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
    2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
    3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
    4. Vanda Presents Phase III Iloperidone Efficacy Data
    5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
    6. Vanda Pharmaceuticals Provides Update on Iloperidone
    7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
    8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
    9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
    10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
    11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2015)... , Aug. 27, 2015  Eli Lilly and Company ... Global Healthcare Conference on Thursday, September 17, 2015. ... of Lilly Oncology and Richard Gaynor , M.D., ... for Lilly Oncology, will participate in a fireside chat ... A live audio webcast will be available on the ...
    (Date:8/27/2015)... 27, 2015  A mere one in seven new ... Hamilton . A new white paper from ... impeding and disrupting manufacturers, success. The white ... Value In Product Development Processes provides insight into: ... how it affects the product development process resulting in: ...
    (Date:8/27/2015)... and TORONTO , Aug. 27, 2015 ... today announced the issuance of a white paper on ... insulin spray product.  The white paper was presented to ... stockholders by Dr. James H. Anderson, Jr. , ... may be viewed online on the Generex website. ...
    Breaking Medicine Technology:Lilly to Participate in Morgan Stanley Global Healthcare Conference 2New White Paper Reveals How Manufacturers Can Improve Product Development Processes 2Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4
    ... Calif., March 24 NuRx,Pharmaceuticals, Inc. (OTC Bulletin Board: ... a Phase I clinical trial of the first-in-class,rexinoid receptor ... expects to complete in the fourth,quarter of this year, ... compound. NRX4204 is the company,s first drug candidate in ...
    ... March 22 Issue of The Lancet -, ... announced that efficacy results of the randomized ... the March 22 issue of The Lancet ... in,combination with 5-fluorouracil/leucovorin (5-FU/LV), a chemotherapy,regimen called ...
    Cached Medicine Technology:NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204 2Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 2Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 3Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 4Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 5
    (Date:8/27/2015)... ... August 27, 2015 , ... King Kullen, America’s First ... Founded by Michael J. Cullen in 1930 and recognized by the Smithsonian Institute as ... Still family owned and operated, the Cullen & Kennedy families have created a culture ...
    (Date:8/27/2015)... ... August 27, 2015 , ... Since its launch on ... having twelve offices in three counties, LA, Orange and San Bernardino. Their ... Founded by Dr. Richy Agajanian, the Oncology Institute of Hope and Innovation ...
    (Date:8/27/2015)... ... 27, 2015 , ... Catalent Pharma Solutions, the leading global ... health products, today announced that Ms. Esther Sadler-Williams, Global Director Strategic Development and ... Radisson Blu Edwardian Hotel, London Heathrow, on September 9th – 10th, 2015. , ...
    (Date:8/27/2015)... ... ... "I need a little help supporting and stabilizing myself when getting into ... "I developed this support handle to give me the extra little boost that I ... a helping hand when stepping into or out of the tub or shower. The ...
    (Date:8/27/2015)... CT (PRWEB) , ... August 27, 2015 , ... ... devices, announces today that they have launched their new corporate website http://www.Z-Medica.com ... site compliments a product-focused website that was launched last year. , “We ...
    Breaking Medicine News(10 mins):Health News:King Kullen Honors Their 85 Years of Success this August 2Health News:California’s Largest Private Oncology Practice Serves 50,000 Patients in 8 years 2Health News:Clinical Trial Supply Chain Logistics to be Discussed By Catalent Expert at Upcoming Flypharma Conference 2Health News:Inventor and InventHelp Client Develops Bathroom Stabilization Aid (LCC-432) 2Health News:Z-Medica® Launches New Corporate Website 2
    ... March 4 STAAR Surgical,Company (Nasdaq: STAA ... invasive ophthalmic products, congratulates Dr. Brian Boxer,Wachler on ... this morning,correcting NBCSports.com columnist Alan Abrahamson,s vision with ... the only foldable, minimally invasive lens approved,in the ...
    ... schools participate in 6th annual KID,HEALTHY--Steps to Healthy ... To combat the,rising trend of childhood obesity ... fifth grade students and parents from Los Angeles,Orange, ... schools and,after-school programs will participate in the KID ...
    ... acute kidney injury (AKI), an external device containing human ... significantly reduces the risk of death, according to a ... the American Society of Nephrology. , The experimental renal ... desperately ill patients with AKI. "Deployment of the ...
    ... Argosy Publishing, an award-winning interactive, visual content ... www.visiblebody.com ), the first free, Web-based 3-D interactive ... developed for educators, and health and medical professionals, ... that demonstrates how the human body works. It ...
    ... Spring Forward - it,s National Sleep Awareness Week, ... physician and,providers at Swedish Medical Center have transitioned ... Sleep Medicine Associates. The new medical group,founded by ... Swedish,Sleep Medicine Institute, will initially operate two centers ...
    ... the Wildlife Conservation Society, the BioDiversity Research Institute, ... environmental mercurymuch of which comes from human-generated emissionsis ... common loons in the Northeast. , The ... symbolic of northern lakes and wildernessappear in the ...
    Cached Medicine News:Health News:STAAR Surgical's Visian ICL Procedure Performed Live on NBC's Today show 2Health News:STAAR Surgical's Visian ICL Procedure Performed Live on NBC's Today show 3Health News:Southern California Parents and Kids Take Healthy Steps in Tackling Childhood Obesity 2Health News:Southern California Parents and Kids Take Healthy Steps in Tackling Childhood Obesity 3Health News:'Renal Assist Device' reduces risk of death from acute kidney failure 2Health News:Argosy publishing launches The Visible Body 2Health News:Argosy publishing launches The Visible Body 3Health News:Sleep Medicine Associates Opens New Doors at Swedish - Cherry Hill Campus 2Health News:Scientists find mercury threatens next generation of loons 2
    The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
    Inquire...
    For use with Snap-In Snap-Out-II tip inserts. Available in five styles, the Snap-In Snap-Out-II Laparoscopic Instrument Handles offer the broadest range available....
    Inquire...
    Medicine Products: